Common Stock, $0.001 par value per share
- Symbol
- GENB
- Exchange
- NASDAQ
- Classification
- COMMON
- Status
- Current
Current Report · Items 2.02, 9.01 · 8-K
Generate Biomedicines, Inc.
GENBNASDAQEQUITYCurrent
Results of Operations and Financial Condition
Item 2.02 Results of Operations and Financial Condition. On August 6, 2026, Generate Biomedicines, Inc. (the "Company") issued a press release reporting its financial results for the quarter ended June 30, 2026. A copy of the Company’s press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K.…
Press release in this filing
Generate Biomedicines Inc. Reports Second Quarter 2026 Financial Results and Provides Business Update →Registered securities in this filing
Generate Biomedicines, Inc. · 8-K · Filed 2026-08-06
Disclosure sections
Item 2.02Item 2.02 - Results of Operations
Item 2.02 Results of Operations and Financial Condition.
On August 6, 2026, Generate Biomedicines, Inc. (the "Company") issued a press release reporting its financial results for the quarter ended June 30, 2026. A copy of the Company’s press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K.
The information in this Current Report on Form 8-K, including Exhibit 99.1 attached hereto, is intended to be furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.
Filed exhibits (1)
EX-99.1 2 ck0002100782-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 Generate Biomedicines Inc. Reports Second Quarter 2026 Financial Results and Provides Business Update SOLAIRIA-1 AND SOLAIRIA-2 Phase 3 studies for GB-0895 (anti-TSLP) in severe asthma continue to advance with recruitment underway across all six global regions Phase 1b data for GB-0895 in COPD to be presented in a poster at the European Respiratory Society (ERS) Congress 2026 on Sept. 8 All patients enrolled in first cohort of the Phase 1 study for GB-4362 (MMAE neutralizer) Platform advancements extend across strategic collaborations Approximately $457.4 million in cash, cash equivalents, and marketable securities as of June 30, 2026 SOMERVILLE, Mass., Aug. 6, 2026 - Generate Biomedicines Inc. (NASDAQ: GENB) (“Generate”) today reported financial results for the second quarter ended June 30, 2026, and highlighted continued progress across its platform, pipeline, and collaborations. “Our team’s focus on execution for our clinical programs and translating our generative biology platform into the next generation of differentiated medicines drove strong progress in the second quarter,” said Mike Nally, chief ex…
Open exhibit ↗